Going into 2024, Treehill expects an even greater degree of scrutiny by boards and investors on the merits of deploying capital from the dwindling cash reserves to conducting clinical studies. We also anticipate a greater degree of accountability and ownership being asked not only of management but also service providers to ensure optimal trial design and trial execution. This will hopefully lead to an improved probability of success and greater return on investment.
See more thoughts from Treehill and other key opinion leaders in the annual Scrip/ Citeline “Scrip Asks – What does 2024 hold for Biopharma (part 2)” here: